# Junta clínica — PT-pseudo_aed2e170b8e6 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_aed2e170b8e6",
  "pid": "PT-pseudo_aed2e170b8e6",
  "task": 1,
  "psa": 86.0,
  "age": 73,
  "months": 1,
  "pirads": "5",
  "psad": 2.306,
  "psav": 14.92,
  "psap": 57.4,
  "vol": 37.29,
  "dre": "Nodus",
  "bx": "Positive",
  "cspca": 0.9527162,
  "medhx": "Not reported",
  "meds": "None",
  "notes": "PSA 86 ng/mL. PI-RADS 5. PSAD 2.31. Prostate volume 37 mL. DRE nodus. csPCa 0.95.",
  "pmhx": [],
  "allergies": [],
  "vitals": {
    "weight": "84 kg",
    "height": "181 cm",
    "bmi": "25.6",
    "bp": "111/74 mmHg",
    "hr": "72 bpm",
    "smoking": "Non-smoker",
    "last_dental": "1 yr ago",
    "flu_vax": "Oct 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "12 Jan 2025",
  "enc_ref": "Dr. R. van den Berg (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Specialist assessment required after confirmed malignancy and subsequent PSA elevation."
    },
    {
      "s": "History",
      "t": "A 73-year-old warehouse manager seeks specialist guidance following prolonged urological tracking. He is married and resides in an independent unit within a retirement community. He is a non-smoker. Lower urinary tract complaints remain minimal, yielding a 4/35 IPSS score. Despite significant anxiety surrounding invasive diagnostics, he requests thorough consultations. His medical history contains no comorbidities, and he takes no active medication, aside from a minor knee arthroscopy more than ten years ago and a recent dermatology check for actinic keratosis monitoring. He explicitly denies bone discomfort, unexplained weight reduction, or blood in the urine."
    },
    {
      "s": "Physical examination",
      "t": "DRE — texture: firm; mobility: fixed; asymmetry: palpable nodus in the right lobe. The remaining abdominal and cardiovascular survey shows no anomalies. Vital signs record 111/74 mmHg with a steady pulse of 72 bpm. He demonstrates adequate perfusion and preserves standard functional capacity."
    }
  ],
  "occupation": "warehouse manager",
  "marital": "Married",
  "living": "Lives in retirement community (independent unit)",
  "next_of_kin": "Adult son (primary contact)",
  "recent_other": [
    "Dermatology — actinic keratosis check"
  ],
  "alcohol": "0 units / week (alcohol-free)",
  "exercise": "Swimming 1x/week",
  "ipss": "IPSS score: 4/35 (mild LUTS)",
  "admin": "Patient anxious about procedures — allocate extra consult time.",
  "mri_hospital": "Maastricht UMC+",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_aed2e170b8e6
Task: 1

Encounter: Urology - outpatient on 12 Jan 2025.
Referrer: Dr. R. van den Berg (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 73-year-old male
  - PSA: 86.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 2.306 ng/mL²
  - PSA velocity: 14.92 ng/mL/yr
  - Prior PSA: 57.4 ng/mL
  - Prostate volume: 37.29 mL
  - Months since last PSA: 1
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.9527162 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 86 ng/mL. PI-RADS 5. PSAD 2.31. Prostate volume 37 mL. DRE nodus. csPCa 0.95.

Vitals: weight 84 kg, height 181 cm, BMI 25.6, BP 111/74 mmHg, HR 72 bpm. Smoking: Non-smoker.

Chief complaint: Specialist assessment required after confirmed malignancy and subsequent PSA elevation.

History: A 73-year-old warehouse manager seeks specialist guidance following prolonged urological tracking. He is married and resides in an independent unit within a retirement community. He is a non-smoker. Lower urinary tract complaints remain minimal, yielding a 4/35 IPSS score. Despite significant anxiety surrounding invasive diagnostics, he requests thorough consultations. His medical history contains no comorbidities, and he takes no active medication, aside from a minor knee arthroscopy more than ten years ago and a recent dermatology check for actinic keratosis monitoring. He explicitly denies bone discomfort, unexplained weight reduction, or blood in the urine.

Physical examination: DRE — texture: firm; mobility: fixed; asymmetry: palpable nodus in the right lobe. The remaining abdominal and cardiovascular survey shows no anomalies. Vital signs record 111/74 mmHg with a steady pulse of 72 bpm. He demonstrates adequate perfusion and preserves standard functional capacity.

Patient info: warehouse manager; Married; Lives in retirement community (independent unit).
Next of kin: Adult son (primary contact).

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Swimming 1x/week; IPSS score: 4/35 (mild LUTS).

Recent other appointments: Dermatology — actinic keratosis check.
Admin: Patient anxious about procedures — allocate extra consult time.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: NO BIOPSY   p(biopsy) = 0.43
  uncertainty  +/- 0.16 epistemic (95% band 0.12-0.73); among patients I cannot tell apart the outcome was 0.99 of 1.00 mixed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. My criterion answers DEFER.

The criterion: PSA >= 20 ng/mL in a man with a tissue diagnosis: the next step is staging and treatment, not more tissue. In the labelled series this criterion matched the reading urologist in 5 of 6 cases in exactly this situation.

Like Expert 1, I have read ONLY the visible panel — not the mpMRI prose, the PSA trajectory, the
previous notes or the laboratory panel. Departing from me needs a specific finding from a document
somebody actually opened, named out loud; not a restatement of the panel numbers I already used.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 49 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 0.93: PI-RADS 5, PSA 113.0, PSAD 2.61, age 67, DRE Nodus -> DEFER (clear). He wrote: "Patient has a verified PCa with PSA 113. Start treatment and do I PSMA-PET for further workup."
  2. distance 1.10: PI-RADS 5, PSA 187.0, PSAD 3.26, age 75, DRE Nodus -> BIOPSY (clear). He wrote: "Very High PSA. Most likely metastatic"
  3. distance 1.50: PI-RADS 5, PSA 190.0, PSAD 4.097, age 66, DRE Nodus -> DEFER (clear). He wrote: "Patient with a clear PCa diagnosis. Do PSMA-PET and start hormontreatment"

PRECEDENT: DEFER (weighted vote 0.34 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 49 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes.
WHAT HE WEIGHS: bx=decisive, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The EAU guidelines state that a PI-RADS score of 3 or higher is used to trigger a biopsy. "A PI-RADS threshold of $\ge 3$ is used to trigger biopsy." This requires the conference to assess if the patient's PI-RADS score meets this threshold.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
EXPERT-STRUCTURED's suggestion of no biopsy is not decisive because the guideline makes the PI-RADS score a direct trigger. EXPERT-COHORT's criterion, which defers based on a prior positive biopsy, is not decisive because the guideline does not specify a definitive action for this specific combination of prior positive biopsy and high PI-RADS score.

WHAT THE DOCUMENTS MUST SETTLE
previous_notes - the prior biopsy status: at Positive the guideline requires assessment of the patient's current clinical status relative to the indication.
radiology_report - whether the lesion is compared against an earlier study: unchanged does not support re-sampling, new or larger does
psa_trend - the PSA trend: the guideline requires assessment of PSA density in relation to risk factors.
laboratory_results - whether the lesion is compared against an earlier study: unchanged does not support re-sampling, new or larger does

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges on whether the PI-RADS 5 score, combined with the prior positive biopsy, mandates a biopsy according to the EAU guidelines.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Does the lesion size and zone, and whether it is compared against an earlier study, support or contraindicate re-sampling?
  psa_trend (get_psa_trend) -> Does the PSA trend, in relation to PSA density and risk factors, support or contraindicate re-sampling?
  previous_notes (get_previous_notes) -> Given the prior positive biopsy status, what is the patient's current clinical status relative to the indication?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. Given the prior positive biopsy, what is the patient's current clinical status relative to the indication, as required by previous notes?

On the plan itself: Dropped 1 question(s) that asked for a value already printed on the panel: "Does the PI-RADS score of 5 meet the EAU threshold for triggering a biopsy?".

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
COMPARISON: new
LESION: size and zone of the index lesion, as the report words it: "discrete hypointense focus within the right mid-gland peripheral zone, spanning roughly 22 mm."
psa_trend
Does the PSA trend, in relation to PSA density and risk factors, support or contraindicate re-sampling? The trend shows a rise from 2.7 (Aug 2023) to 12.2 (May 2024) to 86.0 (Jan 2025), with a PSA density of 2.306 ng/mL/mL.
previous_notes
Given the prior positive biopsy status, what is the patient's current clinical status relative to the indication, as required by previous notes? The notes state: "Urology clinic visit scheduled to track disease progression after the initial positive biopsy. A May 2024 serum test recorded 57.4 ng/mL, warranting continued monitoring. Recent escalation to 86.0 ng/mL has triggered another clinical review."

WHAT I DID NOT OPEN
family-history of prostate cancer (anamnesis) because it is not directly relevant to the immediate decision based on the opened documents.

WHAT THIS SUPPORTS
FOR sampling this patient now
PI-RADS 5 score, as per the EAU guideline, is a direct trigger for biopsy.
PSA trend shows a significant rise, indicating progression since the last assessment.
radiology_report indicates a discrete lesion of 22 mm size in the peripheral zone.
AGAINST sampling this patient now
Prior positive biopsy status, as per the cohort criterion, suggests deferral based on the established criterion.

WHERE THIS LEANS
The PI-RADS 5 score strongly supports proceeding with a biopsy according to the EAU guideline, despite the prior positive biopsy.
LEAN: biopsy

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: INDETERMINATE (uncertain). Last value 86.00 ng/mL over 3 points spanning 17 months; velocity +57.84 ng/mL per year; doubling time about 3 months.
PROJECTION at 6 months: 80.5 ng/mL, conformal 95% band 23.1-280.4.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report — the laboratory panel was not opened, so that block is imputed and my band is wider for it; nothing from the previous notes or the PSA series.

SUGGESTION: NO BIOPSY   p(biopsy) = 0.47
  uncertainty  +/- 0.13 epistemic (95% band 0.21-0.73), of which 0.01 comes from values that had to be imputed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 59% of the time over the 29 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  DEFER, p(biopsy)=0.43  ('discuss' tier; weight 1.0)
  EXPERT-FUSION      DEFER, p(biopsy)=0.47  ('discuss' tier, fusion_nolab; weight 1.5)
  EXPERT-LIBRARY     DEFER, p(biopsy)=0.34  (k=3 precedents; does not vote)
  EXPERT-COHORT      DEFER  (rule psa_ge_20; does not vote)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: cohort criterion (psa_ge_20) — carried by EXPERT-COHORT.
PANEL ANSWER: NO BIOPSY. It matched the reading urologist in 5 of 6 labelled cases in exactly this situation (prior positive biopsy).

Confidence the trace model expects here: clear. Weights it expects: bx=decisive, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents opened by the registrar—the radiology report, PSA trend, and previous notes—directly address the questions posed by the moderator and the requirements set by the EAU guideline specialist.

ALIGNMENT WITH THE PANEL
The retrieved evidence is mixed regarding the decision. The registrar found a significant PSA rise (from 57.4 to 86.0) and a PI-RADS 5 score, which supports biopsy per the EAU guideline. However, the panel protocol's final answer is NO BIOPSY, driven by the cohort criterion (PSA $\ge 20$ ng/mL in a patient with a tissue diagnosis).

THE OPEN QUESTIONS, ONE BY ONE
Q1. Given the prior positive biopsy, what is the patient's current clinical status relative to the indication, as required by previous notes? The previous notes state that the recent escalation to 86.0 ng/mL has triggered another clinical review, which is the clinical status relative to the indication.

WHAT CARRIES WEIGHT, AND WHY
The PI-RADS 5 score is highly relevant as the EAU guideline explicitly uses this as a trigger for biopsy. The PSA trend, showing a significant rise, indicates disease progression. The prior positive biopsy status is the primary factor leading to the panel's deferral.

MY SUGGESTION TO THE CHAIR
I suggest leaning towards biopsy because the PI-RADS 5 score meets the EAU guideline's direct trigger threshold, which should override the cohort criterion when a high-risk imaging finding is present.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: NO BIOPSY   (confidence: clear)

73y male, PSA 86.0 ng/mL, PI-RADS 5, prior positive biopsy. High PSA and known cancer status dictate staging and treatment over repeat biopsy. The prior biopsy grade is not recorded, but the current high PSA and PI-RADS 5 are sufficient for definitive management. Staging and treatment plan.

What carried weight: bx=decisive, age=important, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted
Sections retrieved: radiology_report, psa_trend, previous_notes
